cabergoline has been researched along with Movement Disorders in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (70.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Appiah-Kubi, LS; Chaudhuri, KR; Marco, AD | 1 |
| Battaglia, A; Bracco, F; Chouza, C; Dupont, E; Gershanik, O; Marti Masso, JF; Montastruc, JL | 1 |
| Comella, C; Widnell, KL | 1 |
| Ahlskog, JE; Lieberman, A; Maraganore, DM; Matsumoto, JY; Muenter, MD; Wheeler, K; Wright, KF | 1 |
| Adler, CH; Ahlskog, JE; Muenter, MD; Wright, KF | 1 |
| Bonuccelli, U; Colzi, A; Del Dotto, P; Dubini, A; Grimaldi, R; Lucetti, C; Pardini, C | 1 |
| Catz, T; Inzelberg, R; Kippervasser, S; Korczyn, AD; Nisipeanu, P; Orlov, E; Rabey, JM; Schechtman, E | 1 |
| Bédard, PJ; Di Paolo, T; Goulet, M; Grondin, R | 1 |
| Bracco, F; Chouza, C; Dupont, E; Gershanik, O; Marsden, CD; Marti Masso, JF; Montastruc, JL; Rinne, UK | 1 |
| Bédard, PJ; Di Paolo, T; Goulet, M; Grondin, R; Morissette, M | 1 |
2 review(s) available for cabergoline and Movement Disorders
| Article | Year |
|---|---|
Use of the dopamine agonist cabergoline in the treatment of movement disorders.
Topics: Antiparkinson Agents; Cabergoline; Disease Models, Animal; Dopamine Agonists; Ergolines; Humans; Movement Disorders; Neuroprotective Agents; Parkinson Disease | 2002 |
Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations.
Topics: Apomorphine; Benzophenones; Cabergoline; Catechol O-Methyltransferase Inhibitors; Catechols; Dopamine Agonists; Ergolines; Humans; Levodopa; Movement Disorders; Nitriles; Nitrophenols; Parkinson Disease; Tolcapone | 2005 |
5 trial(s) available for cabergoline and Movement Disorders
| Article | Year |
|---|---|
The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
Topics: Adult; Aged; Antiparkinson Agents; Cabergoline; Case-Control Studies; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Ergolines; Female; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Motor Activity; Movement Disorders; Parkinson Disease; Risk Factors; Time Factors; Treatment Outcome | 2004 |
Fluctuating Parkinson's disease. Treatment with the long-acting dopamine agonist cabergoline.
Topics: Adult; Aged; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1994 |
Adjunctive cabergoline therapy of Parkinson's disease: comparison with placebo and assessment of dose responses and duration of effect.
Topics: Adult; Aged; Antiparkinson Agents; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Ergolines; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1996 |
Double-blind comparison of cabergoline and bromocriptine in Parkinson's disease patients with motor fluctuations.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Bromocriptine; Cabergoline; Double-Blind Method; Ergolines; Female; Humans; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1996 |
Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group.
Topics: Activities of Daily Living; Antiparkinson Agents; Cabergoline; Dopamine Agonists; Double-Blind Method; Ergolines; Female; Humans; Levodopa; Linear Models; Male; Middle Aged; Movement Disorders; Parkinson Disease; Time Factors | 1998 |
3 other study(ies) available for cabergoline and Movement Disorders
| Article | Year |
|---|---|
Cabergoline improves motor disability without modifying L-dopa plasma levels in fluctuating Parkinson's disease patients.
Topics: Analysis of Variance; Antiparkinson Agents; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Treatment Outcome | 1995 |
Cabergoline, a long-acting dopamine D2-like receptor agonist, produces a sustained antiparkinsonian effect with transient dyskinesias in parkinsonian drug-naive primates.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Cabergoline; Catecholamines; Dopamine Agonists; Ergolines; Female; Macaca fascicularis; Motor Activity; Movement Disorders; Putamen; Stereotyped Behavior | 1996 |
Differential regulation of striatal preproenkephalin and preprotachykinin mRNA levels in MPTP-lesioned monkeys chronically treated with dopamine D1 or D2 receptor agonists.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Benzazepines; Brain Chemistry; Cabergoline; Corpus Striatum; Denervation; Dopamine Agents; Dopamine Agonists; Enkephalins; Ergolines; Female; Gene Expression; Macaca fascicularis; Movement Disorders; Protein Precursors; Pulsatile Flow; Receptors, Dopamine D1; Receptors, Dopamine D2; RNA, Messenger; Tachykinins | 1999 |